---
title: Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
nct_id: NCT00136578
overall_status: COMPLETED
phase: PHASE1
sponsor: GlaxoSmithKline
study_type: INTERVENTIONAL
primary_condition: Solid Tumours
countries: United States, United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00136578.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00136578"
ct_last_update_post_date: 2017-09-25
last_seen_at: "2026-05-12T07:33:50.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

**Official Title:** A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Carboplatin on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors.

**NCT ID:** [NCT00136578](https://clinicaltrials.gov/study/NCT00136578)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** GlaxoSmithKline
- **Conditions:** Solid Tumours
- **Start Date:** 2004-10-20
- **Completion Date:** 2006-10-25
- **CT.gov Last Update:** 2017-09-25

## Brief Summary

The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

* Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy.
* ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.

Exclusion criteria:

* Females who are pregnant or nursing.
* Pre-existing hemolytic anemia.
* Pre-existing peripheral neuropathy greater than or equal grade 2. Greater than or equal to 4 prior chemotherapy regimens including neoadjuvant/adjuvant chemotherapy, except breast cancer subjects who may have received more than 4 prior chemotherapy regimens.
* Absolute neutrophil count less than 1,500/mm3.
* Platelets less than 100,000/mm3.
* Hemoglobin less than 9 g/dL.
* Total bilirubin greater than1.5 mg/dL.
* AST/ALT greater than 2.5 X upper limit of normal.
* Creatinine clearance less than or equal to 50 mL/min (calculated by the Cockcroft Gault Formula).
* Known contra-indications to the use of carboplatin, cisplatin, or other platinum-containing compounds.
```

## Arms

- **Subjects receiving carboplatin and SB-715992** (EXPERIMENTAL) — Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.

## Interventions

- **SB-715992** (DRUG) — SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
- **carboplatin** (DRUG) — Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.

## Primary Outcomes

- **Safety and tolerability endpoints will consist of the valuation of adverse events (AEs),vital signs and laboratory values. A dose regimen where = 1 of 6 (or =17%) subjects experience a dose-limiting toxicity.** _(time frame: Up to Day 154)_

## Secondary Outcomes

- **Antitumor activity will be assessed every 2 cycles and will be recorded as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).** _(time frame: Up to 140)_

## Locations (2)

- GSK Investigational Site, Nashville, Tennessee, United States
- GSK Investigational Site, Newcastle upon Tyne, Northumberland, United Kingdom

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.gsk investigational site|nashville|tennessee|united states` — added _(2026-05-12)_
- `locations.gsk investigational site|newcastle upon tyne|northumberland|united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00136578.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00136578*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*